Infant Formula
Infant Formula
Manufactured breast-milk substitute. The regulatory floor is solid (the US FDA requires minimum levels of 30 nutrients including iron, iodine and vitamin D); the open question is whether the premium additives (prebiotics, probiotics, long-chain polyunsaturated fatty acids such as ARA and DHA) deliver the developmental benefits printed on the tin.
What the evidence supports
- Safety and adequacy: formulas have generally proved safe in trials; health bodies say mothers who cannot breast-feed or must top up "should not worry".
- Breast-feeding's advantages over any formula are well established: lower infant infection rates across many studies; lower asthma and allergy rates in several recent ones; far cheaper even counting the mother's extra calories. The FDA and most rich-country bodies call it optimal.
The additive claims
Audit in the BMJ (2023), 757 products, 15 countries: brain/eye/nervous-system development was the most common claim (just over half of products claiming any benefit). Evidence trail:
- 3/4 of products cited no scientific reference
- of references cited, half were clinical trials
- of those, under a third were registered
- among registered randomised trials, 9 in 10 claims rested on evidence the trial authors themselves rated high-risk-of-bias; industry funding common
Formula is regulated as food, not medicine, so claims need no trial backing. High bias risk does not prove the claims false; it leaves them unproven.
LCPUFA (ARA/DHA) evidence, both directions
| Finding | Study |
|---|---|
| No gain in brain development or visual acuity | review of 15 RCTs, 1,889 infants (last updated 2017) |
| No academic edge in adolescence | 1,607 British adolescents fed supplemented formula as infants (2021) |
| Slight, statistically significant cognitive gain | meta-analysis of 9 RCTs, 1,039 infants, Nutrients (2025) |
| Preterm babies may benefit most | FDA note on other studies |
Net: small if real, most plausible in preterm infants, not established for term babies.
Open questions
- Whether the 2025 positive signal holds in larger, independently funded trials.
- Whether premium-additive marketing measurably reduces breast-feeding initiation or duration (the article's stated worry; not quantified in the source).
Related
- How Good Is Infant Formula (Economist) — source.
Research notes, not medical advice. Findings are reported with the population, dose and duration they were measured in; whether they transfer to you is a question for a clinician.